Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Payables (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Payables data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Payables rose 112.51% year-over-year to $5.9 million; the TTM value through Sep 2025 reached $5.9 million, up 112.51%, while the annual FY2024 figure was $3.4 million, 85.2% up from the prior year.
  • Payables reached $5.9 million in Q3 2025 per ABEO's latest filing, down from $7.3 million in the prior quarter.
  • Across five years, Payables topped out at $7.3 million in Q2 2025 and bottomed at $1.5 million in Q2 2021.
  • Average Payables over 5 years is $3.1 million, with a median of $2.8 million recorded in 2024.
  • Peak YoY movement for Payables: tumbled 58.13% in 2022, then soared 136.75% in 2025.
  • A 5-year view of Payables shows it stood at $4.3 million in 2021, then crashed by 58.13% to $1.8 million in 2022, then rose by 2.6% to $1.9 million in 2023, then soared by 85.2% to $3.4 million in 2024, then soared by 72.25% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $5.9 million in Q3 2025, $7.3 million in Q2 2025, and $5.0 million in Q1 2025.